Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions
Diabetes Obes Metab
.
2024 May 15.
doi: 10.1111/dom.15638.
Online ahead of print.
Authors
Hayase Hakariya
1
2
,
Mutsuko Ohnishi
3
,
Tetsuya Tanimoto
4
Affiliations
1
Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen, Germany.
2
Institute for Pharmaceutical and Social Health Sciences, Kyoto, Japan.
3
Medical Governance Research Institute, Tokyo, Japan.
4
Navitas Clinic, Tokyo, Japan.
PMID:
38747140
DOI:
10.1111/dom.15638
No abstract available
Grants and funding
Toyobo Biotechnology Foundation